Clinical trial
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With…
NCT00237185 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00237185 |
|---|---|
| Title | A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene |
| Official title | Open, Randomized, Phase II Study of Glivec in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Plus 10 Year Extension Study |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST) |
| Intervention type | Drug |
| Interventions | Imatinib mesylate |
| Enrollment | 148 |
| Start date | Jun 1, 2000 |
| Primary completion | Jun 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Oct 12, 2005 |
| Last update posted | Aug 19, 2014 |
| Countries | Australia, Finland, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: